Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
YZ-0235
- Development stage
- Preclinical
- Lead developer
- Guangdong Yinzhu Pharmaceutical Technology
- Modality
- Small Molecules
01
Overview
YZ-0235 is a preclinical-stage small molecule inhibitor targeting the NF-κB (nuclear factor kappa-light-chain-enhancer of activated B cells) pathway. Developed by Guangdong Yinzhu Pharmaceutical Technology, it is being investigated for the treatment of ALK-positive non-small cell lung cancer (NSCLC), specifically in combination with the ALK inhibitor alectinib. The rationale for this combination likely involves overcoming resistance mechanisms or enhancing the apoptotic effect of ALK inhibition through the modulation of NF-κB signaling, which is often implicated in cell survival and drug resistance in various cancers.
Beyond the preview
Go deeper on YZ-0235.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on YZ-0235.